Global private equity and venture capital news and research

Posts Tagged ‘RiverVest Venture Partners’

6 May 2015

RiverVest to target pharma, medical devices with new $80.2m fund

pharmaceutical-12_sq Life sciences-focused RiverVest Venture Partners plans to target the pharmaceutical and therapeutic medical device sectors after closing its third fund on just over $80m.

14 April 2015

RiverVest collects $75m for third VC fund

norway-river-1445165-1-m Life science-focused RiverVest Venture Partners has moved over the halfway mark for its $150m third fund, AltAssets understands.

3 April 2014

RiverVest promotes O’Donnell to MD, hires Berman as venture partner

river-rapids Life sciences-focused RiverVest Venture Partners has promoted Niall O’Donnell to managing director and hired Mike Berman as a venture partner.

12 March 2014

RiverVest backs $13.3m financing round for energy monitoring company Smart Wire Grid

California-based energy monitoring system developer Smart Wire Grid has raised just under $13.4m from RiverVest Venture Partners.

16 July 2013

RiverVest Venture Partners exits IDEV Technologies for 2.6x return

RiverVest Venture Partners has exited its portfolio company IDEV Technologies, which was sold for $310m to Abbott Laboratories.

15 March 2013

Life sciences investor RiverVest Venture Partners acclaims Fund II IRR

Life science-focused investment firm RiverVest Venture Partners has confirmed its Fund II has yielded a 14.5 per cent per annum net IRR since inception.

7 January 2013

Life sciences company Tryton Medical closes $24m financing round

Life sciences company Tryton Medical has closed $24m in financing. All current investors participated in the financing, which was led by sector-focused investment firm PTV Sciences.

17 December 2012

Novo Ventures leads $32m financing for biotech company Allakos

virus2_sq Denmark-based Novo Ventures has led a $32m Series A preferred stock financing round for antibody-focused biotechnology company Allakos.

29 October 2012

Texas pharmaceutical company ZS Pharma closes $46m venture round

blood_vein_170sq Texas-based pharmaceutical company ZS Pharma has raised $46m to advance the development of ZS-9, a crystal form of zirconium silicate designed to treat patients with kidney and liver disease.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016